Arcus Biosciences (Arcus Biosciences) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Arcus Biosciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Arcus Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Arcus Biosciences's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Arcus Biosciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Arcus Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcus Biosciences LT-Debt-to-Total-Asset Chart

Arcus Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.07

Arcus Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Arcus Biosciences LT-Debt-to-Total-Asset Calculation

Arcus Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	1095
	=	0.00

Arcus Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0	/	1293
	=	0.00

Arcus Biosciences (NYSE:RCUS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Arcus Biosciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Arcus Biosciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcus Biosciences (Arcus Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcus Biosciences Inc (NYSE:RCUS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3928 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.arcusbio.com

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.

Executives

Goeltz Ii Robert C.	officer: Chief Financial Officer	343 OYSTER POINT BLVD, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Juan C. Jaen	director, 10 percent owner, officer: President	850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043
Jennifer Jarrett	officer: See Remarks	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Alexander Azoy	officer: Chief Accounting Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Terry J Rosen	director, 10 percent owner, officer: Chief Executive Officer	C/O TULARK INC, TWO CORP DRIVE S, SAN FRANCISCO CA 94080
Carolyn C. Tang	officer: General Counsel	3928 POINT EDEN WAY, HAYWARD CA 94545
Dimitry Sa Nuyten	officer: Chief Medical Officer	740 HEINZ AVENUE, C/O ADURO BIOTECH, INC., BERKELEY CA 94710
Linda Slanec Higgins	director	3610 LOUIS RD., PALO ALTO CA 94303
Nicole Lambert	director	322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
William Grossman	officer: Chief Medical Officer	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Yasunori Kaneko	director, 10 percent owner	509 ROEHAMPTON, HILLS BOROUGH CA 94010
Kathryn E Falberg	director	C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael Quigley	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Andrew J Perlman	director	618 MIRADA AVE, STANFORD CA 94305